Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients

AIDS

Volumn 27, Issue 7, 2013, Pages 1187-1188

  Vispo, Eugenia ^a   Fernandez Montero, José Vicente ^a   Labarga, Pablo ^a   Barreiro, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ETRAVIRINE; HEPATITIS B SURFACE ANTIGEN; NEVIRAPINE; RALTEGRAVIR; VIRUS RNA;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SIDE EFFECT;

ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; MALE; NEVIRAPINE; OLIGOPEPTIDES; PYRIDINES; PYRROLIDINONES; RITONAVIR; SULFONAMIDES;

EID: 84879099266     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cb815     Document Type: Article

References (8)

1. Rodríguez-Rosado R, García-Samaniego J, Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998; 12:1256.
2. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
3. Soriano V, Puoti M, Garcia-Gasco P, Rockstroh J, Benhamou Y, Barreiro P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13.
4. Jones M, Nuñez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012; 32:167-176.
5. Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, et al. J Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/HCV co-infected patients. J Antimicrob Chemother 2011; 66:2605-2614.
6. Macías J, Neukam K, Portilla J, Iribarren JA, de los Santos I, Rivero A, et al. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2011; 66:1346-1350.
7. Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012; 13:127-131.
8. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670-676. Educación en SIDA